Project example 3: Oral anti-platelet therapy

Project type	Cost-effectiveness analysis
Indication	Cardiovasculare events
Intervention	Oral anti-platelet therapy
Methods	Literature review Markov modeling
Countries	UK
Deliverables	Journal article
Publications	Oral antiplatelet therapy in secondary prevention of cardiovascular events: an assessment from the payer's perspective. Heeg B, Damen J, van Hout B. Pharmacoeconomics 2007; 25(12): 1063-82. Long-term clopidogrel therapy in patients receiving percutaneous coronary intervention. Heeg BM, Peters RJ, Botteman M, van Hout BA. Pharmacoeconomics 2007; 25(9): 769-82. Cost-effectiveness of clopidogrel vs. aspirin treatment in high-risk acute coronary syndrom patients in Denmark. Heeg B, van Gestel A, van Hout B, Olsen J, Haghfelt TH. Ugeskr Laeger 2006; 168(35): 2911-5.

Pharmerit was invited by the editor of Pharmacoeconomics to apply a previously developed Markov model for oral antiplatelet therapies in the prevention of cardiovascular events to the results of recent trials: ESPRIT, CHARISMA, CAPRIE, CURE, ESPS 2, PCI-CURE, CREDO and CLARITY. The results from the modeling exercise were compared to those found in a comprehensive literature review including 21 studies. The model results were analyzed in view of the NICE guidelines for the use of oral antiplatelets for the prevention of cardiovasculare events. The methods and results of this self-funded project have been reported in a journal article.